Senti Biosciences Holdings (SNTI) Total Debt (2021 - 2024)

Senti Biosciences Holdings (SNTI) posted quarterly Total Debt of $20000.0 for Q3 2024, little changed quarter-over-quarter from $20000.0 in Q2 2024.

Senti Biosciences Holdings (SNTI) Total Debt (2021 - 2024) Analysis & Trends

Senti Biosciences Holdings' Total Debt history runs 2 years deep, the most recent figure standing at $20000.0 for Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	546.77 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	9.34 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	770.36 Mn
10	Senti Biosciences Holdings	13.66 Mn	13.66 Mn	-	3.99 Mn

Download Data